TITAN PHARMACEUTICALS, INC.

BUPEPLANT

Pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction and pain management; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases;

BUPLANT

Pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction and pain management; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases;

CCM

FAMILY OF CELL-BASED PREPARATIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS CONSISTING OF THERAPEUTIC CELLS ADHERED TO INERT MICROCARRIERS FOR DIRECT IMPLANTATION INTO THE BRAIN OR SPINAL CORD;

CEAVAC

pharmaceutical preparations, namely, anti-cancer vaccines;

INNOVATIONS IN MEDICINE

pharmaceutical preparations for use in treating cancer, central nervous system disorders and conditions related to central nervous system disorders;MEDICINE;

INNOVATIONS IN MEDICINE

Pharmaceuticals, namely, pharmaceuticals for the treatment of central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular diseases, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular diseases, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; and anti-cancer vaccines;MEDICINE;

NUVALA

Pharmaceutical preparations for the treatment of schizophrenia;The wording NUVALA has no meaning other than trademark significance.;

PIVANEX

pharmaceuticals for the treatment of cancer;

PROBUFAN

Pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction and pain management; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases;

PROBUPHINE

Pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases;

PROBUPHINE

The mark consists of the word PROBUPHINE, and the I in PROBUPHINE has four diagonal lines above it.;Pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and lifethreatening diseases;Color is not claimed as a feature of the mark.;